Novelion Therapeutics Observes Rare Disease Day
February 28 2019 - 07:00AM
Novelion Therapeutics Inc. (NASDAQ: NVLN), a
biopharmaceutical company dedicated to developing new standards of
care for individuals living with rare diseases, today announced its
alliance with the National Organization for Rare Disorders (NORD),
Rare Diseases Europe (EURORDIS), Canadian Organization of Rare
Disorders (CORD), and The Global Genes Project, among others, in
observance of the annual Rare Disease Day.
Interim Chief Executive Officer Ben Harshbarger
commented, “Today we join with others in the community to raise
awareness of rare diseases. The theme of this year’s Rare Disease
Day is Bridging Health and Social Care, highlighting the existing
gaps between medical, social and support services that present
challenges for families living with a rare disease. We are honored
to have the opportunity to contribute by supporting our patients
and continuing to deliver much needed therapies to those in
need.”
In the United States, a rare disease is defined
as one that affects fewer than 200,000 persons. According to the
National Institutes of Health (NIH), there are nearly 7,000 rare
diseases affecting nearly 30 million Americans. Rare Disease Day
was established by EURORDIS and was first observed in Europe in
2008. In 2009, EURORDIS partnered with NORD for this initiative in
the U.S. For more information about Rare Disease Day, visit
www.rarediseaseday.us or www.rarediseaseday.org.
About Novelion Therapeutics
Novelion, through its subsidiary Aegerion Pharmaceuticals, is a
global biopharmaceutical company dedicated to developing and
commercializing therapies that deliver new standards of care for
people living with rare and underserved metabolic diseases. Our
goal is to develop and bring to market transformational therapies
that have the potential to significantly change the treatment
paradigm for patients affected by a variety of rare and metabolic
diseases, including diseases associated with low leptin. With a
global footprint and an established commercial portfolio, including
MYALEPT® (metreleptin) and JUXTAPID® (lomitapide), our business is
supported by differentiated treatments that treat severe and rare
diseases.
CONTACT:
Amanda Murphy, Director, Investor Relations & Corporate
CommunicationsNovelion
Therapeutics857-242-5024amanda.murphy@novelion.com
Novelion Therapeutics (NASDAQ:NVLN)
Historical Stock Chart
From Feb 2024 to Mar 2024
Novelion Therapeutics (NASDAQ:NVLN)
Historical Stock Chart
From Mar 2023 to Mar 2024